Purpose: To investigate the association of plasma and vitreous leucine-rich-α2-glycoprotein (LRG1) with diabetic retinopathy (DR) progression. VSports手机版.

Methods: A total of 86 outpatients and 33 inpatients were recruited. Outpatients with type 2 diabetes mellitus (T2DM) were classified as T2DM without DR (n = 22), nonproliferative DR (NPDR) (n = 20) and proliferative DR (PDR) (n = 22) based on international clinical DR severity scales. A total of 86 plasma and 33 vitreous samples were collected and subjected to enzyme-linked immunosorbent assay V体育安卓版. The diagnostic value of plasma LRG1 was tested using receiver operating characteristic (ROC) curves. .

Results: Plasma LRG1 in PDR patients (9025 ± 1870 pg/ml) was significantly increased as compared with controls (5975 ± 2022 pg/ml), T2DM without DR (6550 ± 2359 pg/ml) and NPDR patients (6550 ± 2359 pg/ml) (p < 0. 0001). Vitreous LRG1 in PDR patients was elevated by approximately 4. 3-fold than that in controls (562. 1 ± 273. 5 ng/ml versus 130. 0 ± 102. 8 ng/ml, p = 0. 000). The area under the ROC curve value for plasma LRG1 was 0 V体育ios版. 786 (p < 0. 0001). The maximal Youden index was 0. 4372 and the optimal cut-off value of LRG1 was 7357. 043 pg/ml with 81. 82% sensitivity and 61. 90% specificity. .

Conclusion: Plasma and vitreous LRG1 levels were elevated in patients with PDR VSports最新版本. Leucine-rich-α2-glycoprotein (LRG1) might be a potential risk-warning marker for PDR. .